Literature DB >> 22894951

Future therapies for food allergy.

Laurie M McWilliams1, Talal Mousallem, A Wesley Burks.   

Abstract

Food allergy affects 3.9% of US children and is increasing in prevalence. The current standard of care involves avoidance of the triggering food and treatment for accidental ingestions. While there is no current curative treatment, there are a number of therapeutic strategies under investigation. Allergen specific therapies include oral and sublingual immunotherapy with native food protein as well as recombinant food proteins. Allergen non-specific therapies include a Chinese herbal formula (FAHF-2) and the use of anti-IgE monoclonal antibody therapy. Although none of these treatments are ready for clinical use, these therapeutic strategies present promising options for the future of food allergy.

Entities:  

Keywords:  anaphylaxis; desensitization; food allergy; oral immunotherapy; subcutaneous immunotherapy; sublingual immunotherapy; tolerance

Mesh:

Year:  2012        PMID: 22894951      PMCID: PMC3660769          DOI: 10.4161/hv.20868

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  43 in total

1.  Oral immunotherapy with immunodominant T-cell epitope peptides alleviates allergic reactions in a Balb/c mouse model of egg allergy.

Authors:  P Rupa; Y Mine
Journal:  Allergy       Date:  2011-09-27       Impact factor: 13.146

2.  Birch-apple syndrome treated with birch pollen immunotherapy.

Authors:  Marina Mauro; Marina Russello; Cristoforo Incorvaia; Gianbattista Gazzola; Franco Frati; Philippe Moingeon; Gianni Passalacqua
Journal:  Int Arch Allergy Immunol       Date:  2011-08-10       Impact factor: 2.749

3.  Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization.

Authors:  Edwin H Kim; J Andrew Bird; Michael Kulis; Susan Laubach; Laurent Pons; Wayne Shreffler; Pamela Steele; Janet Kamilaris; Brian Vickery; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2011-02-01       Impact factor: 10.793

4.  A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy.

Authors:  Hugh A Sampson; Donald Y M Leung; A Wesley Burks; Gideon Lack; Sami L Bahna; Stacie M Jones; Dennis A Wong
Journal:  J Allergy Clin Immunol       Date:  2011-03-11       Impact factor: 10.793

5.  Fatalities due to anaphylactic reactions to foods.

Authors:  S A Bock; A Muñoz-Furlong; H A Sampson
Journal:  J Allergy Clin Immunol       Date:  2001-01       Impact factor: 10.793

6.  A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response.

Authors:  Pooja Varshney; Stacie M Jones; Amy M Scurlock; Tamara T Perry; Alex Kemper; Pamela Steele; Anne Hiegel; Janet Kamilaris; Suzanne Carlisle; Xiaohong Yue; Mike Kulis; Laurent Pons; Brian Vickery; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2011-03       Impact factor: 10.793

7.  Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance.

Authors:  Brian P Vickery; Laurent Pons; Michael Kulis; Pamela Steele; Stacie M Jones; A Wesley Burks
Journal:  Ann Allergy Asthma Immunol       Date:  2010-12       Impact factor: 6.347

Review 8.  Oral immunotherapy for IgE-mediated cow's milk allergy: a systematic review and meta-analysis.

Authors:  J L Brożek; L Terracciano; J Hsu; J Kreis; E Compalati; N Santesso; A Fiocchi; H J Schünemann
Journal:  Clin Exp Allergy       Date:  2012-03       Impact factor: 5.018

9.  Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy.

Authors:  K Roy; H Q Mao; S K Huang; K W Leong
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

10.  Effect of anti-IgE therapy in patients with peanut allergy.

Authors:  Donald Y M Leung; Hugh A Sampson; John W Yunginger; A Wesley Burks; Lynda C Schneider; Cornelis H Wortel; Frances M Davis; John D Hyun; William R Shanahan
Journal:  N Engl J Med       Date:  2003-03-10       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.